In brief. No specific antiviral against BK virus exists today. Faced with reactivation, nephrologists have a single lever: reduce immunosuppression so the patient’s own immunity can contain the virus — at the risk of triggering graft rejection. BKNeutrol, the drug candidate developed by SPyDiag in Tours, inverts that logic. It is a bispecific antibody directed against the VP1 capsid protein, designed to neutralise genotypes I and IV — 95% of reactivations — without touching immunosuppressive therapy. The programme has validated in vitro proof of concept and is entering regulatory toxicity evaluation ahead of a first phase I trial.
Close to 100,000 kidney transplants are performed worldwide every year. For a significant share of these patients, a quiet threat settles in during the months that follow: reactivation of BK polyomavirus. Here is why this virus is so difficult to control, and how a new therapeutic approach intends to change the balance.
A silent threat to the graft
BK polyomavirus is among the most widespread human viruses: close to 90% of adults carry it. Primary infection occurs in childhood by the aerodigestive route; the virus then disseminates and becomes dormant in the renal epithelium, where it persists latently for life. Several genotypes are distinguished: genotype I is the most common at around 80%, followed by genotype IV at around 15%, with types II and III accounting for the remaining 5%.
In a healthy person the virus causes nothing at all — the immune system holds it in check. The problem begins when that immune surveillance is deliberately lowered, which is precisely what happens after a transplant.
Why transplantation wakes the virus
To prevent rejection of the transplanted kidney, patients receive immunosuppressive therapy. Modern agents such as tacrolimus and mycophenolate mofetil have sharply reduced acute rejection, but at the cost of deeper immunosuppression. In that setting BK virus regains room to replicate, and reactivation progresses in stages.
| Stage | Proportion of recipients | What happens |
|---|---|---|
| Viruria | 30–40% | The virus reappears in urine during the first two years after transplantation. |
| Viremia | 20–25% | Replication intensifies; tubular lesions let the virus into the bloodstream. |
| Nephropathy at five years | 6–7% | Tubulointerstitial nephropathy establishes itself and damages the graft. |
| Graft loss | Up to 5% | Graft failure and return to dialysis. |
The current dilemma: fight the virus or protect the graft
This is where the whole problem lies. With no specific antiviral available, the only weapon is to reduce immunosuppression and give the immune system the means to control the virus. But lowering that guard exposes the graft to rejection — the very complication the entire treatment strategy exists to prevent.
The clinician therefore walks a ridge line, continually adjusting the balance between viral replication and rejection risk. Hence the importance of early detection: the sooner reactivation is identified, the wider the window for action. That is the purpose of the UriFastBK urinary test, SPyDiag’s diagnostic programme, designed to detect replication quickly without depending on batched PCR turnaround.
BKNeutrol: neutralising the virus without lowering the guard
BKNeutrol proposes a change of paradigm. Rather than weakening the patient’s immunity in order to reach the virus, the treatment targets the virus itself.
The principle is a bispecific antibody directed against VP1, the major capsid protein — the shell of BK virus. By binding VP1, the antibody neutralises viral particles and blocks their capacity to infect new cells. Designed to recognise both genotype I and genotype IV, it covers 95% of observed reactivations.
The clinical advantage is direct: by neutralising the virus at source, BKNeutrol would allow immunosuppressive therapy to be maintained rather than reduced. The patient would remain protected against rejection while the infection is controlled — with the objective of fewer graft losses and longer graft survival.
Where BKNeutrol stands
BKNeutrol is a drug candidate in development, not an available treatment. The programme is clearing its regulatory stages one after another: research and development complete, in vitro proof of concept validated, regulatory toxicity evaluation under way, phase I clinical trial to come.
The in vitro proof of concept is solid. The current step is regulatory toxicity assessment, a mandatory precondition for a first phase I trial. SPyDiag notes that no preclinical efficacy model exists for this indication — a particularity of BK virus, which infects only humans.
Several other anti-VP1 monoclonal antibody programmes are in clinical development elsewhere, which validates the target while defining the competitive landscape.
Detect early, treat precisely
The coherence of the project lies in pairing diagnosis with therapy. On one side, UriFastBK to detect reactivation early and often; on the other, BKNeutrol to treat it in a targeted way. Together they outline comprehensive management of the kidney transplant recipient, from screening through to treatment — exactly where, today, there is only surveillance and compromise.
Frequently asked questions
Is there a specific treatment for BK virus after kidney transplantation?
No. No specific antiviral is approved to date. Management rests on reducing immunosuppressive therapy so the immune system can control the virus, at the cost of increased rejection risk.
Why is BK virus dangerous for a transplanted kidney?
Because the immunosuppressants given after transplantation lower the patient’s defences. In that setting 30 to 40% of recipients reactivate the virus within two years, and 20 to 25% develop viremia. Progression to BK nephropathy, with an incidence of 6 to 7% at five years, can lead to graft loss in up to 5% of patients.
How does BKNeutrol act against BK virus?
The antibody binds the VP1 capsid protein and neutralises viral particles, blocking spread. The aim is to control infection directly, without reducing immunosuppression and therefore without exposing the patient to rejection.
Which genotypes does BKNeutrol target?
The two most common: type I at around 80% and type IV at around 15%, together representing 95% of BK virus reactivations.
Is BKNeutrol available today?
No. The programme has validated in vitro proof of concept and is entering regulatory toxicity evaluation, the step preceding a first phase I trial.
Further reading
- BK virus nephropathy: natural history and impact on the graft
- BKNeutrol — the immunotherapy programme in full
- UriFastBK — rapid urinary diagnosis of BK virus
General information provided for educational purposes; it does not replace medical advice. BKNeutrol and UriFastBK are research programmes in development and are not available health products. For any question about your own situation, consult your transplant team.